OTHER INFORMATION
−Removed: On March 11, 2024 , Neil Peterson , our Chief Operating Officer , adopted a trading arrangement (the “Peterson Rule 10b5-1 Trading Plan”) for the sale of shares of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c).
−Removed: The Peterson Rule 10b5-1 Trading Plan, which has a term of approximately one year , provides for sales of up to 7,500 shares of Common Stock pursuant to the terms of the plan.
−Removed: On March 15, 2024 , Raul Parra , our Chief Financial Officer and Treasurer, adopted a trading arrangement (the “Parra Rule 10b5-1 Trading Plan”) for the sale of shares of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c).
−Removed: The Parra Rule 10b5-1 Trading Plan, which has a term of approximately 22 months , provides for the sale of shares of Common Stock issuable under the terms of certain performance stock units granted to Mr.
−Removed: Parra by Merit.
−Removed: The exact number of shares of Common Stock that will be issued to Mr.
−Removed: Parra under the terms of the applicable performance stock units, and then subject to sale pursuant to the terms of the Parra Rule 10b5-1 Trading Plan, is currently unknown and will depend upon the achievement of certain corporate financial metrics.
−Removed: Other than with respect to the Peterson Rule 10b5-1 Trading Plan and the Parra Rule 10b5-1 Trading Plan, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408 during the three-month period ended March 31, 2024.
−Removed: The foregoing description of the Peterson Rule 10b5-1 Trading Plan and the Parra Rule 10b5-1 Trading Plan are summaries only and are qualified in their entirety by reference to those plans, copies of which are attached as Exhibit 10.1 and Exhibit 10.2, respectively, to this Quarterly Report on Form 10-Q.
+Added: During the fiscal quarter ended June 30, 2024, none of our directors or officers informed us of the adoption or termination of a “Rule 10 b5-1 trading arrangement” or “non-Rule 10 b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408 .
+Added: Asset Purchase Agreement, dated July 1, 2024, by and between Merit Medical Systems, Inc.
+Added: and Endogastric Solutions, Inc.
Second Amended and Restated Articles of Incorporation.*
−Removed: Third Amended and Restated Bylaws.*
−Removed: Rule 10b5-1 Trading Plan, dated March 11, 2024, between Neil W.
−Removed: Peterson and Morgan Stanley Smith Barney LLC.
−Removed: Rule 10b5-1 Trading Plan, dated March 15, 2024, between Raul Parra and Morgan Stanley Smith Barney LLC.
−Removed: Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, by and between Merit Medical Systems, Inc.
−Removed: and Fred Lampropoulos.†
−Removed: Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, by Merit Medical Systems, Inc.
−Removed: and each of the following individuals:
−Removed: Raul Parra, Neil Peterson, Brian Lloyd and JoeWright.†
−Removed: Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, by Merit Medical Systems, Inc.
−Removed: and Mike Voigt.†
−Removed: Restricted Stock Unit Award Agreement, dated March 9, 2024, by and between Merit Medical Systems, Inc.
−Removed: and Fred Lampropoulos.†
−Removed: Form of Restricted Stock Unit Award Agreement, dated March 4, 2024, by Merit Medical Systems, Inc.
+Added: Fourth Amended and Restated Bylaws.*
+Added: Indemnification Agreement dated May 15, 2024 between Merit Medical Systems, Inc.
+Added: and Silvia M.
+Added: Form of Restricted Stock Unit Award Agreement, dated May 16, 2024, by and between Merit Medical Systems, Inc.
and each of the following individuals:
−Removed: Raul Parra, Neil Peterson, Brian Lloyd and Joe Wright.†
−Removed: Restricted Stock Unit Award Agreement, dated March 8, 2024, by Merit Medical Systems, Inc.
−Removed: and Mike Voigt.†
+Added: Carpenter, Stephen C.
+Added: Evans, David K.
+Added: Floyd, Thomas J.
+Added: Gunderson, Laura S.
+Added: Kaiser, Michael R.
+Added: McDonnell, F.
+Added: Ann Millner, Lynne N.
+Added: Ward and Silvia M.
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 .
2 unchanged sentences
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 .
−Removed: The following financial information from the quarterly report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL):
+Added: The following financial information from the quarterly report on Form 10-Q for the quarter ended June 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL):
(i) Consolidated Balance Sheets, (ii) Consolidated Statements of Income, (iii) Consolidated Statements of Comprehensive Income (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) related Condensed Notes to the Unaudited Consolidated Financial Statements, tagged in detail.
4 unchanged sentences
MERIT MEDICAL SYSTEMS, INC.
−Removed: April 30, 2024
+Added: August 1, 2024
Lampropoulos, President and
Chief Executive Officer
−Removed: April 30, 2024
+Added: August 1, 2024
/s/ RAUL PARRA
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.